Protocol Ledger

NCT06235216 · Phase II · RECRUITING

Sacituzumab govitEcan in THYroid Cancers

Interventional Phase II clinical trial protocol NCT06235216 sponsored by Grupo Espanol de Tumores Neuroendocrinos in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-13 Enrollment: 42 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06235216
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06235216
Protocol FieldVerified Registry Value
NCT IdentifierNCT06235216
Consolidated Lead SponsorGrupo Espanol de Tumores Neuroendocrinos
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment42 participants (ESTIMATED)
Registered Start Date2024-09-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI